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Introduction
Treatment options for vitiligo are limited and many cases remain 
refractory to first and second line treatments. Interferon-gamma 
signaling mediated by Janus kinase (JAK) has been implicated in the 
pathogenesis of vitiligo.1 Systemic administration of tofacitinib, a 
potent JAK1/3 inhibitor, has been effective in treating vitiligo in case 
reports,2 however, it is associated with infections, malignancies, 
cytopenias, gastrointestinal perforations, and hyperlipidemia in some 
patients with rheumatoid arthritis. Topical administration of tofacitinib 
may limit unintended systemic effects, and herein we present the 
experience with topical tofacitinib 2% cream in the treatment of 
patients with non-segmental vitiligo.
Material and Methods
This nonrandomized cohort study was conducted in collaboration 
between the Department of Dermatology at Brigham and Women’s 
Hospital, Boston, Massachusetts and the Department of Dermatology 
at the University of California, Irvine. The Institutional Review Boards at
both institutions approved this protocol.  Prescription records were 
reviewed for patients receiving a prescription for 2% topical tofacitinib 
cream compounded in a liposomal cream by ChemistryRx in 
Philadelphia. Patients were prescribed tofacitinib 2% cream twice daily 
to target areas. Concomitant treatment with topical steroids, topical 
calcineurin inhibitors, supplements (e.g. Polypodium Leucotomos and 
Gingko biloba), or phototherapy was allowed. Patients who received 
concomitant phototherapy received one of the following: booth NBUVB,
PUVA, or excimer laser treatment. Corresponding medical records 
including clinical notes and photographs were reviewed. The primary 
outcome measure was the change in pigmentation of treated target 
lesions as measured by BSA. A two-tailed, two sample t-test was used 
to evaluate the relationship between categorical variables and 
repigmentation of target lesions. A simple linear regression was used 
to evaluate the relationship between age of onset and duration of 
disease with repigmentation.
Results
Sixteen patients with vitiligo received prescriptions for 2% tofacitinib 
cream and were evaluated during a follow-up visit. Half the patients 
were female, and the ethnic distribution was: 10 Caucasians, 1 Latino, 
1 East Asian, and 4 South Asians. Seven patients were Fitzpatrick type 
II, 4 were type III, 2 were type IV, and 3 were type V. Three patients 
had focal facial vitiligo, 2 had focal non-facial vitiligo, while 11 had 
generalized vitiligo. The mean age was 55.125 [16-78]. Average follow-
up time was 153 days [63-367]. The average length of time since onset
of vitiligo was 13.9 years. All but one patient was previously treated 
with topical steroids, topical calcineurin inhibitors, and/or 
phototherapy. Thirteen experienced repigmentation with 4 patients 
experiencing >90% repigmentation; 5 patients experiencing 25-75% 
repigmentation; and 4 patients experiencing 5-15(%) repigmentation. 
Two patients experienced no change; and 1 patient experienced slow 
progression of depigmentation in the target lesion (Table 1). Facial 
lesions improved more than non-facial lesions (p=0.0216), and 
patients with Fitzpatrick skin type IV-VI improved more than individuals
with lighter skin types (p=0.03434). Gender (p=0.8327) and age at 
diagnosis (r = -0.2232) were not correlated with repigmentation. There
was a moderate negative correlation of duration of disease with 
repigmentation (r = -0.4669).
Acne-like papules on the face were reported by 1 patient. These 
lesions resolved with cessation of the medication. One patient reported
subtle skin contour changes on his chin which led to cessation of 
treatment after 2 weeks. No other adverse events were reported.
Discussion
Herein we present a series of 16 patients with vitiligo treated with 
topical tofacitinib. Topical JAK inhibition offers the promise of targeted 
therapy with minimal systemic side effects, however, the published 
experience to date is limited to 9 patients treated with ruxolitinib3 and 
a series of 11 patients treated with tofacitinib for facial vitiligo.4 This 
series extends previous observations and demonstrates the potential 
of benefit for at least some patients with non-facial lesions. 
Consistent with previously published results, robust responses were 
noted on facial lesions. We also noted greater responses in patients 
with darker skin types. While effects on non-facial lesions were minimal
(average of 16% repigmentation), 5 of 8 patients treating non-facial 
targets experienced some improvement. One patient experience 95% 
repigmentation of focal lesions in the axilla and on the right torso. This 
patient was 16-years-old at the age of treatment, was Fitzpatrick Skin 
Type V, and had only focal lesions occupying <1% BSA, suggesting 
that topical tofacitinib may be effective for non-facial lesions if the 
patient exhibits other favorable prognostic indicators (e.g. younger 
age, darker skin type, and focal disease). In contrast with previously 
reported studies suggesting that concomitant light exposure may be 
required for response,5 there was not a clear pattern in our series with 
respect to response and concomitant phototherapy. Our study may not
have been sufficiently powered to detect the effect of phototherapy, 
however.
While this study is small, uncontrolled, and occurred in the setting of 
concomitant treatments, it suggests that topical administration of 
tofacitinib is safe and efficacious. Future randomized controlled studies
or larger cohorts should be performed to confirm these observations 
and identify patients most likely to benefit from JAK inhibition.
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Table 1. Clinical characteristics, concurrent treatments, and response
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